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Abstract 
Introduction: Duramycin through binding with phosphatidylethanolamine (PE) has 
shown potential to be an effective anti-tumour agent. However its mode of action in 
relation to tumour cells is not fully understood. 
  
Methods: PE expression on the surface of a panel of cancer cell lines was analysed 
using duramycin and subsequent antibody labelling then analysed by flow 
cytometry. Cell viability was also assessed via flow cytometry using annexin V and 
propidium iodide (PI). Calcium ion (Ca2+) release by tumour cells in response to 
duramycin was determined by spectrofluorometry following incubation with Fluo-3, 
AM. Confocal microscopy was performed on the cancer cell line AsPC-1 to assess 
real time cell response to duramycin treatment. 
 
Results: Duramycin was able to detect cell surface PE expression on all 15 cancer 
cell lines screened, which was shown to be duramycin concentration dependent. 
 However higher concentrations induced necrotic cell death. Duramycin induced 
calcium ion (Ca2+) release from the cancer cell lines also in a concentration and 
time dependent manner. Confocal microscopy showed an influx of PI into the cells 
over time and induced morphological changes. 
 
Conclusion: Duramycin induces Ca2+ release from cancer cell lines in a time and 
concentration dependent relationship. 
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Introduction 
 
Duramycin is a 19-amino acid tetracyclic peptide produced from Streptoverticillium 
cinnamoneus [1, 2]. It is one of very few known, relatively, small peptides to have 
a defined 3-dimensional structure. This structure is stable [3] due to the presence 
of 4 covalent intra-molecular bridges formed from the amino acids lanthionine, 
methyllanthionine, lysinoalanine and beta-hydroxyaspartic acid [4]. Due to the 
presence of these amino acids duramycin is designated as a Type B lantibiotic. Its 
stability also means that duramycin is resistant to both thermal and proteolytic 
degradation [3].  Duramycin’s binding site confers specific physiochemical 
interactions that selectively recognise the ethanolamine headgroup of the 
aminophospholipid phosphatidylethanolamine (PE) [5]. The binding of duramycin to 
PE is on a 1:1 molar ratio and at high affinity with dissociation constants in the low 
nanomolar range (4-6nM) [6, 7]. PE is a phospholipid ubiquitously found in 
eukaryotic cell membranes. In quiescent cells PE is primarily located on the inner 
cell membrane along with the aminophospholipid phosphatidylserine (PS) [8-10]. 
This membrane asymmetry is enzymatically maintained [8, 11, 12] by ATP-
dependent aminophospholipid translocases that are responsible for the inward and 
outward movement of PE and PS. Upon activation PE can become exposed on the 
outer cell membrane [13] which is important in a number of physiological processes 
for example in apoptosis and necrosis [14], membrane re-organisation in 
cytokinesis [15] and the initiation of coagulation [16, 17]. 
 
It has been reported in the literature that duramycin has an effect on cell 
membranes. Duramycin, through binding with PE, has been seen to change vesicle 
membranes into highly curved tubular structures [6], change the shape of PE 
containing monolayers and reduce lipid order [18]. It has been shown to have the 
ability to form channels in both artificial and biological membranes [19], 
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permeabilise cells at concentrations of >50µM [20, 21] and destroy cell membranes 
[22]. Adding to its ability to disturb cell membranes duramycin has been reported 
to effect ion movement in a range of cell types. Duramycin displayed inhibitory 
effects on chloride (Cl-) transport in bovine clathrin-coated vesicles [23], the 
sodium-potassium ATPase pump through inhibition of phosphoenzyme formation 
[24] and a magnesium dependent ATPase in plasma membranes [20]. Duramycin 
also disrupted ATP dependent calcium ion (Ca2+) uptake in vesicles from rabbit 
sarcoplasmic reticulum [21]. Duramycin has been shown to have stimulatory 
effects on ion movement leading to the release of intracellular ions or the elevation 
of intracellular ion concentration. This has been observed in human colonic epithelia 
[19, 25], cardiomyocytes [26] and airway epithelia [22, 27, 28]. A number of 
studies have investigated Ca2+ release in response to duramycin [22, 28] due to 
duramycin’s ability to release this ion from the airway epithelia from intracellular 
stores at low concentrations and from both intracellular stores and extracellular 
influx at higher concentrations [28]. Due to its presumed action on calcium 
activated chloride channels (CACC) duramycin reached clinical trials for the 
treatment of cystic fibrosis (CF) [29, 30]. 
 
Exposure of cell surface PE has been reported to be up-regulated in cancer cells 
[31] and found to be expressed on the endothelium of tumour vasculature of many 
different forms of tumour in vitro and in vivo [1] and on the surface of cancer cell 
derived microparticles [32]. Through the targeting of PE duramycin has been used 
to successfully image prostate tumour endothelium in rats [1]. PE therefore has the 
potential to be a wide-ranging tumour marker for a variety of malignancies. 
Duramycin’s specificity, stability and fast renal clearance time [33] make it an ideal 
probe for PE. Further duramycin has been shown to disrupt cancer cell derived 
microparticle mediated coagulation [34] and have anti-proliferative and anti-
tumour effects on pancreatic cancer cell lines [31]. 
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In this study the effect of duramycin on Ca2+ release in ovarian and pancreatic 
cancer cell lines was investigated. As duramycin is known to interact with cancer 
cell lines it may be important to discern the effects on ion movement, membrane 
integrity and channel formation in cancer cell lines as has been observed in other 
cell types. Duramycin has the potential to be an effective anti-tumour therapy 
agent however it’s mode of action in relation to tumour cells is not fully understood. 
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Materials and Methods 
 
Cell Culture 
The cell lines AsPC-1, Caco-2, Colo320, HCT116, JJN3, Lovo, MCF7, MDA-MB-231, 
MIA PaCa-2, MM.1S and U266B1 were purchased from the American Type Culture 
Collection (UK). The cell lines A2780, SK-OV-3, T47D and U937 were purchased 
from European Collection of Cell Cultures (UK). All cell lines were cultured in 
accordance with distributor’s recommendations. Each cell line was cultured using 
either DMEM, RPMI, IMDM or McCoy's 5a Medium Modified (Lonza, UK) with FBS 
(Bio-Sera, UK) and (v/v); 100 units/ml penicillin, 100 µg/ml streptomycin (P/S) 
(Lonza, UK). All serum, P/S and buffers added to media were filtered through a 
0.2µm filter before addition. Between use all media was stored at 2-8°C. All cell 
lines were incubated at 37°C in a 5% CO2 atmosphere except for MDA-MB-231 
which was incubated at 37°C in a 0% CO2 atmosphere. All cell lines were cultured 
in tissue culture flasks (Sarstedt, UK) and removed when cells were either adherent 
and in the logarithmic growth phase or removed when at a high enough growth 
density for suspension cell lines. 
 
Flow Cytometric Phosphatidylethanolamine Detection 
Cells (2 x 105) were re-suspended in 50µl PBS and added to a 5ml polypropylene 
tube (Sarstedt, UK). Then either 10µl of duramycin (duramycin from 
Streptoverticillium cinnamoneus, Sigma-Aldrich, UK) at appropriate concentration 
or 10µl normal rabbit serum (1:5000 dilution) as negative control was added to the 
tube and incubated at room temperature for 30 minutes. Cells were washed with 
PBS, centrifuged at 320g for 3 minutes and re-suspended in 300µl PBS and 10µl of 
anti-duramycin antibody (Abcam, UK) (final dilution 1:600) was added and 
incubated in the dark at room temperature for 30 minutes. The cells were then 
washed and re-suspended as before and 50µl of sheep anti-rabbit IgG:FITC 
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antibody (AbD Serotec®) (final dilution 1:600) added and incubated in the dark at 
room temperature for 30 minutes. Cells were washed, centrifuged and re-
suspended as before and then analysed using a BD FACScalibur (BD Biosciences, 
UK), which was the flow cytometer, used for all flow cytometric analysis in this 
study. Data is expressed as median fluorescence intensity (MFI) ratio which is 
calculated by division of the MFI value for the positive sample by the MFI value of 
the negative control sample giving the level of shift in fluorescence intensity of a 
population of cells expressed as a ratio. 
  
Flow Cytometric Cell Viability Analysis 
Cell viability was analysed using the Annexin V: FITC Apoptosis Detection Kit I from 
BD Biosciences, UK and protocol followed manufacturer’s instructions. Briefly, cells 
(2 x 105) were re-suspended in 50µl PBS and added to a 5ml polypropylene tube. 
The cells were treated with an appropriate concentration of duramycin and 
incubated for 30 minutes at room temperature. After washing cells were re-
suspended in 100µl binding buffer (1:10 dilution) and incubated with 5µl Annexin 
V: FITC and 5µl propidium iodide (PI) for 15 minutes in the dark at room 
temperature. After this 300µl binding buffer was added and cells analysed by flow 
cytometry.  
 
Forward Scatter and Side Scatter Data Collection 
The data used for the forward and side scatter analysis was gathered from an 
investigation into the effect of duramycin treatment on cell viability at time points 
over a 2 hour time course (not included in this publication). These cells were 
processed using the flow cytometric cell viability analysis method described above.  
 
Ca2+ Signalling Detection Assay 
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Cells were removed from tissue culture flask after treatment with 2ml trypsin 
incubated for 5 minutes at 37°C and 5% CO2. After the cells were washed with PBS 
and centrifuged at 320g for 5 minutes they were re-suspended in 0.5ml fresh 
media, 1.3 µl of 100mM sulphinpyrazone and 5µl of Fluo-3, AM (stock solution 
2.19mM) (Life Technologies, UK) and incubated for 30 minutes. Cells were then 
washed and centrifuged at 320g for 5 minutes and re-suspended in calcium buffer 
(150mM NaCl, 3mM KCl, 10mM glucose, 20mM HEPES and 2.5µM sulphinpyrazone, 
adjusted to pH 7.5). When required the buffer included 1.5mM calcium chloride. 
Cells (1 x 105) were added to a cuvette containing 1.9ml calcium buffer to make up 
to 2ml and placed in a spectrofluorometer. Duramycin (20µl) at appropriate 
concentration or calcium ionophore A23187 (Sigma-Aldrich, UK) (12µl) was added 
to the cuvette. All data was analysed using FeliX GX software (Photon Technology 
International, UK). The percentage calcium ion release from duramycin treated cells 
was calculated as a percentage of the total calcium ion release from the control 
cuvette treated with the calcium ionophore A23187 [28]. 
 
Confocal Microscopy 
For study of cell viability and cell membrane appearance, cell membranes were 
dyed using the CellVue® Jade Cell Labelling Kit (eBioscience, UK) using 
manufacturer’s instructions. Briefly, cells (2 x 107) were re-suspended in 1ml of 
diluent C and added to 1ml of diluent C containing 4µM dye solution and incubated 
for 3 minutes with periodic mixing. After being washed with PBS 250µl cells (2 x 
105) were incubated with 12.5µl PI (BD Biosciences, UK) for cell nucleus staining for 
15 minutes at room temperature in the dark. The cells were then transferred to 
lumox® dishes and analysed using a Zeiss LSM 710 confocal microscope and Zen 
software version X (Zeiss, UK).  
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For the study of Ca2+ present in cells, 2.6µl of 100mM sulphinpyrazone was added 
to cells (1x106) in 1ml PBS. The dye Fluo-3, AM (10µl of 2.19mM) (Life 
Technologies, UK) was added to the cell suspension and incubated at room 
temperature in the dark for 30 minutes while gently rocked. After being washed 
with PBS, cells (8 x 105) were re-suspended in 1ml warm PBS and incubated with 
1x CellMask™ Orange Plasma membrane Stain (Life Technologies, UK) for 10 
minutes in the dark at 37°C. After cells were washed and re-suspended in warm 
PBS, 250µl cells (2 x 105) were transferred to lumox® dishes and analysed using 
the Zeiss LSM 710 confocal microscope and Zen software version X (Zeiss, UK). 
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Results 
 
Duramycin Detection of PE 
A total of 15 different cancer cell lines, accounting for 6 different cancer types, 
were screened using flow cytometry for cell surface expression of PE. All the cell 
lines screened had detectable levels of PE on the cell surface (Figure 1).  Median 
fluorescence intensity (MFI) ratios were used to express relative PE levels on the 
cancer cell lines. The majority of the cancer cell lines had relatively low MFI ratios 
i.e. between 1.00 (minimum detectable expression) and 1.80. An exception to this 
was the 3 multiple myeloma (MM) cell lines which had MFI ratios ranging from 2.15 
to 3.75. The ovarian cancer cell lines A2780 and SK-OV-3 and the pancreatic cancer 
cell lines AsPC-1 and MIA PaCa-2 were investigated further. Due to the MM cell 
lines being a circulating form of tumour they were not investigated. All of the 4 
cancer cell lines showed an increase in PE MFI ratio with increased duramycin 
concentration (Figure 2). The relationship between PE detection and duramycin 
concentration showed a strong correlation for all 4 cell lines with Pearson 
Correlation Coefficient’s of r = 0.80, 0.84, 0.76 and 0.87 for A2780, AsPC-1, MIA 
PaCa-2 and SK-OV-3 respectively. AsPC-1 had the highest increased MFI ratio from 
1.1 at the screening concentration of duramycin (2.5µM) to 4.5 at the highest 
duramycin concentration (1mM). The concentration of duramycin used in flow 
cytometric PE detection (2.5µM) was a compromise on what would be optimal 
detection concentration (200µM-1mM) due to the cytotoxic effects of duramycin at 
these higher concentrations. 
 
Duramycin Induced Necrotic Cell Death 
The 2 ovarian cancer cell lines and the 2 pancreatic cancer cell lines described 
above were assessed for cell viability after treatment with a series of duramycin 
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concentrations via flow cytometry with a dual Annexin V: FITC and PI stain. All 4 
cell lines showed an increase in percentage necrotic cells in a duramycin 
concentration dependent manner (Figure 3). Duramycin had its highest cytotoxic 
effect (87-96% necrosis) at concentrations above 500µM. The threshold 
concentration for inducement of cell death in the cancer cell lines was 5µM; 
concentrations below this did not induce necrosis. 
 
Ca2+ Release in Response to Duramycin 
Intracellular calcium ion (Ca2+) release upon treatment with duramycin was 
investigated using a spectrofluorometric method. The Ca2+ release was expressed 
as a percentage of the total Ca2+ released from cells that were treated with the 
control calcium ionophore. All 4 cell lines tested were found to release intracellular 
Ca2+ upon treatment with duramycin in a concentration dependent manner (Figure 
4). Percentage Ca2+ release was investigated both in the presence and absence of 
extracellular Ca2+ but no significant difference was seen between the conditions. 
The amount of Ca2+ release and percentage necrosis of cells was not found to 
correlate when cells were treated with duramycin concentrations below 10µM. 
There was only a significant increase in Ca2+ release and necrotic cell death 
observed in the cancer cell lines when treated with 50µM duramycin. 
 
The time taken to reach peak Ca2+ release also followed a duramycin concentration 
dependent trend (Figure 5). For all 4 cell lines investigated this time was extended 
when the cells were in the presence of extracellular Ca2+. This extension in time 
taken to reach peak Ca2+ release varied between cell lines, for example when cells 
were treated with 50µM duramycin the time difference between cell lines ranged 
from 14 seconds (AsPC-1) to 91 seconds (A2780). Due to the release of Ca2+ in 
response to duramycin treatment it was plausible that Ca2+ release was a method 
of duramycin induced cell death. However, a sustained influx and efflux of Ca2+ was 
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seen up to 1hr after duramycin treatment suggesting maintained membrane 
integrity. 
 
Duramycin Induced Cell Morphology Change 
Analysis of forward scatter (FSC) and side scatter (SSC) data obtained from flow 
cytometry showed little change in cell size but some change in cell complexity when 
cancer cell lines were treated with a series of duramycin concentrations. The same 
4 cancer cell lines were subjected to treatment with duramycin between 2.5µM and 
1mM and analysed for change in scatter properties along a 2 hour time course. 
A2780, MIA PaCa-2 and SK-OV-3 showed no significant change in FSC over the 
time course for all duramycin concentrations. AsPC-1, however, showed a slight 
increase in FSC when treated with 50µM, 200µM and 1mM duramycin. For example, 
FSC at 30 minutes for untreated AsPC-1 cells was 351.1 compared to 528.2 when 
treated with 1mM duramycin. All 4 cancer cell lines increased in SSC when treated 
with 200µM and 1mM duramycin with peak increase occurring at 1 hour after 
treatment. 
 
Confocal Microscopy 
To further investigate the effect of duramycin on cancer cell membranes and any 
possible pore forming the pancreatic cancer cell line AsPC-1 was studied using 
confocal imaging. Over 20 minutes of 50µM duramycin treatment AsPC-1 cells 
showed a marked loss of cell membrane stain (Figure 6 and 7). There was an 
approximate 51% reduction of cells over the 20 minutes retaining the staining. This 
would suggest a loss in cell membrane integrity or cell death. Some cell membrane 
staining loss could also be accounted for by the destabilisation of the dye 
compound as the untreated control cells saw a 28% reduction in cell numbers with 
cell membrane staining. Uptake of PI from the buffer solution into the AsPC-1 cells 
over the 20 minutes can be seen by an increase in cell numbers with cell nucleus 
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staining (Figure 6 and 7). Over the time course there was a 62% increase in the 
number of cells with cell nucleus staining when treated with duramycin compared to 
the untreated control cells in which there was a 1.6% increase. 
 
AsPC-1 cells were exposed to 50µM duramycin treatment over 30 minutes and 
imaged, using confocal microscopy, for Ca2+ release. Over the 30 minutes, from 2 
minutes onwards, there was a significant loss in Fluo-3, AM dye (Figure 8) 
suggesting a leakage of Ca2+ out of the cell. There was a 13% increase in cell 
numbers dyed with cell membrane stain over the 30 minutes. Untreated control 
cells at 30 minutes and 60 minutes saw maintained membrane integrity with the 
Ca2+ dye remaining inside the cells (Figure 9). 
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Discussion 
 
Duramycin was used to detect the cell surface presence of PE on a number of 
different cancer cell types. In this way it was used as a screening method for 
confirmation of the expression of PE by a diverse range of cancer cell types. All of 
the cancer cell lines showed detectable levels of PE to varying amounts. Levels of 
expression did not appear to be cancer type specific with the exception of the MM 
cell lines which had a relatively higher PE expression than the other cancer cell 
lines. 
 
Further investigation into 4 of the cell lines: 2 ovarian and 2 pancreatic showed that 
PE detection was strongly correlated with duramycin concentration. This finding is 
confounded when it is taken in to account that duramycin has the ability to induce 
cell death and therefore potentially increase the cell surface expression of PE. The 
compromise between optimal PE detection and duramycin concentration was, 
however, necessary due to the cytotoxic effect of duramycin at higher 
concentrations. Investigations using the same 4 cancer cell lines, as above, showed 
that duramycin is able to induce necrosis in a concentration dependent manner. 
Concentrations above 500µM were able to induce 87-96% necrosis in the cancer 
cell lines. The pancreatic cancer cell line AsPC-1 showed a higher percentage of 
necrosis than the other cell lines at lower duramycin concentrations suggesting a 
higher sensitivity. However this may be due to naturally lower cell viability 
observed with this cell line. The level of cell death at the higher concentrations was 
cancer cell line dependent however all 4 cancer cell lines showed a uniform 
threshold concentration for inducement of cell death of 5µM. Concentrations of 
duramycin ≥3.3µM have been shown to cause ‘leak’ currents in cardiomyocytes 
[26] and concentrations of 100µM and 250µM duramycin inhibited Cl- secretion in 
cystic fibrosis bronchial epithelial cells (CFBE) [22]. It was suggested that this was 
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due to a destruction of the membrane which would support our finding that higher 
duramycin concentrations induce cancer cell necrosis. It has been reported 
previously that pancreatic cancer cell lines undergo apoptosis and then ultimately 
necrosis when treated with relatively low concentrations of duramycin for 48 hours 
[31]. 
 
It is known that duramycin interacts with cell membranes. It was shown that 
duramycin binding to PE modified the membranes of multilamellar vesicles into 
highly curved tubular structures [6] and can form channels in artificial black lipid 
membranes and biological membranes [19]. Duramycin binding to PE has also been 
seen to change the shape of PE monolayers from circular to horseshoe-like and 
reduce lipid order [18]. It is also reported that the peptide elevates intracellular 
calcium levels [28] and in clinical trials, in the treatment of CF, was thought to 
work on CACC [27, 29, 30]. Further investigation by Oliynyk [22] found that 
duramycin did induce chloride (Cl-) secretion from CFBE within a narrow 
concentration range of around 1µM and did not cause secretion in the non-CF 
epithelial counterparts. Intracellular Ca2+ concentration, however, was not found to 
increase in the CFBE cells and yet did in the non-CF human bronchial epithelial cells 
(16HBE). It was suggested that this inferred an efflux of ions from the non-specific 
changes of the cell membrane rather than a specific effect on CACC. 
In this study it was investigated whether duramycin had any specific effect on Ca2+ 
release in cancer cell lines and whether the build-up of intracellular Ca2+ and its 
potential release from the cell could offer an explanation for the duramycin 
mediated cell death seen in the cancer cells. All 4 cell lines investigated were seen 
to release intracellular Ca2+ immediately following the addition of duramycin at 
concentrations of 5µM and above (Figure 4). The percentage Ca2+ release from the 
cells was duramycin concentration dependent. Time taken to reach the peak 
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amount of Ca2+ release increased as duramycin concentration increased and was 
prolonged when cells were in the presence of extracellular calcium. This may 
suggest that duramycin-induced pore formation may increase with an increase in 
duramycin concentration which may explain the higher loss of Ca2+ over a longer 
period of time. The data implies the pores would allow the movement of Ca2+ back 
into the cell due to the prolonged time to reach peak Ca2+ release in the presence 
of extracellular calcium, inferring an influx and efflux of Ca2+. Also when the Ca2+ 
assay was allowed to run for 1 hour after duramycin addition the cancer cells did 
not return to their ground Ca2+ release state, seen with the control ionophore 
A23187, but instead showed a sustained influx and efflux of Ca2+. This finding has 
been observed in airway epithelium in which the effect of duramycin on calcium 
release was sustained compared to the rapid increase seen with the control 
ionophore A23187 [28]. There was a lack of correlation between Ca2+ release and 
necrotic cell death. This would imply that, rather than a loss of Ca2+ triggering an 
internal cell death mechanism, duramycin creates pores that simply allows 
movement of calcium in and out of the cell. Oliynyk suggests a non-specific loss of 
Cl- ions from CF epithelial cells due to duramycin induced membrane changes [22]. 
Duramycin concentrations of ≥0.3µM caused an increase in release of sodium ions 
(Na+) from cardiomyocytes and ≥3.3µM caused an increase in leak current of hERG 
potassium channels and Na+ from the cardiac cells [26]. It has also been seen that 
duramycin causes channel formation and ion release in colonic epithelial cells [19]. 
Due to the similar response of the release and leakage of ions from channels that 
are structurally different [26], from a range of cell types and from the immediacy of 
Ca2+ ion release seen here it is likely that duramycin causes a non-specific pore 
formation in cell membranes. 
 
Alternatively, it is possible that duramycin’s presence causes a destabilisation of the 
cell membrane that then leads to cell death. This is supported by flow cytometric 
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analysis of FSC/SSC data in which SSC immediately increased upon treatment with 
duramycin. This may have been due to internal changes in the cells or a 
destabilisation of the cell membrane. To investigate further the effect of duramycin 
on cancer cell membranes the pancreatic cancer cell line, AsPC-1, which increased 
in FSC was imaged along a time course of duramycin treatment using confocal 
microscopy. When AsPC-1 cells were stained with CellVue® Jade and imaged over a 
30 minute time course of 50µM duramycin treatment there was a significant loss in 
cell numbers dyed with cell membrane stain. This may suggest a loss of membrane 
integrity or cell death. Some of the cells appeared to have increased in size 
supporting the finding of an increase in FSC and possible swelling of the cell. 
Interestingly, staining with CellMask™ Orange showed an increase in cell numbers 
with cell membrane staining over time compared to the decrease seen with 
CellVue® Jade. 
 
Imaging of AsPC-1 cells with confocal microscopy also allowed for observation of an 
increase in PI staining of the cell nuclei and therefore movement of PI from the 
buffer solution into the cell and a loss of Ca2+ stain. Untreated control cells saw an 
increase of 1.6% in cell numbers with cell nucleus staining compared to the 
duramycin treated cells which showed an increase of 62%. The first 2 minutes of 
duramycin treatment increased Ca2+ staining. The most likely explanation for this is 
that as duramycin binds to cell surface PE in these first couple of minutes and the 
non-specific pores are formed there is a sudden increase in release of Ca2+ from 
intracellular stores. This is supported by results seen in the confocal imaging of 
16HBE cells that saw an increase in intracellular Ca2+ concentration when treated 
with 1 and 3µM duramycin [22]. As duramycin, once bound to PE, may change the 
physical properties of the cell membrane and therefore disturb ion channel function 
[26] it is possible that duramycin induced cell death may be a mixture of both loss 
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of intracellular components through membrane pores and the destabilisation of the 
cell membrane. 
 
In addition to its direct anti-tumour properties duramycin has potential as an 
imaging agent for tumours through the targeting of PE. The structure of duramycin 
includes 2 primary amines, cysteine and lysine, at the N-terminal which make 
conjugation of duramycin possible without disrupting the PE binding site [4]. This 
method has been employed to successfully radiolabel duramycin to Technitium-99m 
and image acute cell death in vivo in rat models of acute myocardial infarction [33]. 
This agent was found to have high specificity and stability and a fast renal 
clearance time [33]. Duramycin has also been radiolabelled with Gadolinium [4]. 
Conjugation of duramycin to fluorescent molecules has also been employed in the 
imaging of tumour cells in vitro [5] and the targeting of PE expressed on the 
endothelium of aortic flow dividers [35]. Here duramycin was firstly derivatised 
through biotinylation and then conjugated to an avidin molecule in a 2 step 
labelling technique [5, 35, 36]. This indicates that duramycin, at least in theory, 
has broad practical uses in the targeting of PE on tumour cells. 
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Conclusion 
 
The current study provides evidence to suggest that upon binding to PE duramycin 
induces calcium release from cancer cell lines. It is known that duramycin causes 
ion release from many different cell types however the exact mechanism for this 
remains to be elucidated. The evidence from this study, and others, suggests the 
most likely explanation for this ion release is through duramycin mediated non-
specific pore formation. The release of calcium from the cancer cells was duramycin 
concentration dependent. At higher concentrations duramycin caused cancer cells 
to undergo necrosis. This effect was almost instantaneous, occurring within minutes 
of duramycin treatment, suggesting a rapid loss of membrane stability. Within this 
timeframe it is more likely that duramycin’s effect is that of forming a pore in the 
cell membrane rather than a physiological effect. However further study is required 
to be able to ascertain duramycin’s mode of action on calcium release and 
inducement of cell death in cancer cells. Though yet to be established duramycin 
has the potential to be an effective anti-tumour agent or PE probe in the targeting 
of tumours. 
Use of Duramycin 
Duramycin is not approved for treatment of cancer and so the data presented in 
this work is purely investigational. 
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Legends to Figures 
 
Figure 1. PE expression on 15 different cancer cell lines (6 different cancer types). PE 
expression is given as median fluorescence intensity (MFI) ratio. All of the cancer cell lines 
showed detectable levels of PE at relatively low levels with the exception of the multiple 
myeloma (MM) cell lines (JJN3, MM.1S and U266B1) which had a relatively higher PE 
expression than the other cancer cell lines. Readings are average, n=2. 
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Figure 2. PE detection is duramycin concentration dependent. Optimal PE detection is seen at 
concentrations of 200µM duramycin and above. However the concentration used in this study 
to detect PE was 2.5µM due to duramycin’s induced cell death at higher concentrations. 
Readings were performed in triplicate for each data point. 
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Figure 3. Duramycin mediated cancer cell death is duramycin concentration dependent. 
Concentrations above 500µM were able to induce 87-96% necrosis in the cancer cell lines. All 4 
cancer cell lines showed a uniform threshold concentration for inducement of cell death of 
5µM. AsPC-1 appear to have a higher sensitivity to duramycin however this may be due to a 
naturally lower viability observed in these cells. Readings were performed in triplicate for each 
data point. 
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Figure 4. Intracellular calcium ion (Ca2+) release upon treatment with duramycin. The Ca2+ 
release was expressed as a percentage of the total Ca2+ released from cells that were treated 
with the control calcium ionophore A23187. All 4 cell lines released Ca2+ in a duramycin 
concentration dependent manner. The closed data points represent the presence of 
extracellular calcium and the empty data points the absence. Each data point is the average of 
n=4. 
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Figure 5. Time taken to reach peak Ca2+ release. Time taken to reach peak Ca2+ release was 
duramycin concentration dependent. For all 4 cell lines investigated the time to reach peak 
calcium release was extended when the cells were in the presence of extracellular Ca2+. The 
closed data points represent the presence of extracellular calcium and the empty data points 
the absence. Each data point is an average of n=4. 
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Figure 6. One minute-interval images of AsPC-1 cells over a 20 minute time-course of 50µM 
duramycin treatment. Cells were stained with cell membrane dye CellVue® Jade and cell 
nucleus stain propidium iodide (PI). There was an approximate 51% reduction over the 20 
minutes of cells retaining membrane staining. Uptake of PI from the buffer solution into the 
AsPC-1 cells saw an increase of 62% in the number of cells with cell nucleus staining over the 
20 minutes. 
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Figure 7. Confocal images of AsPC-1 cells. Cells were stained with cell membrane dye CellVue® 
Jade and cell nucleus stain PI. There was an approximate 51% reduction over the 20 minutes of 
cells retaining membrane staining. Uptake of PI from the buffer solution into the AsPC-1 cells 
saw an increase of 62% in the number of cells with cell nucleus staining over the 20 minutes. 
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Figure 8. Confocal images of AsPC-1 cells exposed to 50µM duramycin treatment over 30 
minutes. Cells were stained for cell membrane (CellMaskTM Orange) and Ca2+ (Fluo-3, AM). 
Over the 30 minutes there was a significant loss in Fluo-3, AM dye suggesting a leakage of Ca2+ 
out of the cell. There was a 13% increase in cell numbers dyed with cell membrane stain over 
the 30 minutes. 
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Figure 9. Confocal images of untreated control AsPC-1 cells. Images of cells were taken at 30 
and 60 minutes under the same conditions as the duramycin treated AsPC-1 cells when 
undergoing confocal microscopy. Maintained cell membrane integrity and the Ca2+ dye 
remaining inside the cells can be seen. 
 
